Endomyocardial biopsy in patients with myocarditis—still justified in the CMR era? A single-centre experience
Clinical Research in Cardiology · 2024
DOI: 10.1007/s00392-024-02574-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Research in Cardiology, 2024. Verfasst von Katharina Seuthe und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and University Hospital Cologne, Clinic III for Internal Medicine, University of Cologne, Cologne, Germany. katharina.seuthe@uk-k…. Hauptthemen laut MEDLINE: Myocarditis, Magnetic Resonance Imaging, Cine, Myocardium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Köln.
Abstract (Originalsprache)
Background
In the past decades, cardiovascular magnetic resonance (CMR) was established as a non-invasive tool supporting the diagnosis of myocarditis and there is often reluctance in performing EMB due to potentially severe complications. We sought to identify patient subgroups that could still benefit from EMB in the CMR era.
Methods
Data of patients presenting with myocarditis between 01/2016 and 06/2023 were analysed according to patient risks. Prespecified risk factors were (i) left ventricular ejection fraction (LVEF) ≤ 30%; (ii) severe arrhythmias; or (iii) pre-existing autoimmune disease. Furthermore, the subgroup of recurrent myocarditis cases was analysed separately.
Results
A total of 137 patients (35.5 ± 14.8 years, 80.3% male) were included. 26/137 patients had a documented LVEF ≤ 30%, 13/137 a LVEF > 30% with at least one other risk factor and 98/137 a LVEF > 30% without risk factors. EMB was performed in 21/26 patients with LVEF ≤ 30% (80.8%), in 7/13 patients with LVEF > 30% and risk factors (53.8%) and in 16/98 (16%) patients without risk factors. EMB led to the initiation of immunosuppressive therapy in 11/28 patients with risk factors (39.3%) and in none of the patients without risk factors (0/16, 0%, p = 0.003). With respect to the subgroup of patients presenting with recurrent myocarditis ( n = 10), no specific therapy was initiated.
Conclusions
Due to a high therapeutic yield for initiation of immunosuppressive therapy in non-infectious myocarditis, performing EMB should be considered in all high-risk patients. In patients without clinical risk factors including cases of recurrent or relapsing myocarditis no specific therapy was initiated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine and University Hospital Cologne, Clinic III for Internal Medicine, University of Cologne, Cologne, Germany. katharina.seuthe@uk-koeln.de.
- Faculty of Medicine and University Hospital Cologne, Clinic III for Internal Medicine, University of Cologne, Cologne, Germany.
- Institute for Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Institute for Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany.
- Faculty of Medicine and University Hospital Cologne, Clinic III for Internal Medicine, University of Cologne, Cologne, Germany. henrik.ten-freyhaus@uk-koeln.de.
Förderung
- Universitätsklinikum Köln
Zitieren
APA
Seuthe, K., Pfister, R., Pennig, L., Mons, U., Klingel, K., & Freyhaus, H. T. (2024). Endomyocardial biopsy in patients with myocarditis—still justified in the CMR era? A single-centre experience. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-024-02574-4
Vancouver
Seuthe K, Pfister R, Pennig L, Mons U, Klingel K, Freyhaus HT. Endomyocardial biopsy in patients with myocarditis—still justified in the CMR era? A single-centre experience. Clinical Research in Cardiology. 2024. doi:10.1007/s00392-024-02574-4
BibTeX
@article{Seuthe2024,
author = {Seuthe, Katharina and Pfister, Roman and Pennig, Lenhard and Mons, Ute and Klingel, Karin and Freyhaus, Henrik Ten},
title = {Endomyocardial biopsy in patients with myocarditis—still justified in the CMR era? A single-centre experience},
journal = {Clinical Research in Cardiology},
year = {2024},
doi = {10.1007/s00392-024-02574-4}
}
EUVIMED